Toxoplasma gondii has been described in scientific literature for more than a century, but its reputation has always rested on one central idea. Once the parasite forms cysts inside the brain, it enters a slow and relatively dormant state. It can reactivate under specific conditions, especially when the immune system weakens, but the internal structure of the cyst has long been treated as simple. The parasite was believed to exist as a single, uniform cell type waiting for the right moment to shift back into an active stage. New work from a research team at the University of California Riverside shows that this assumption was incorrect. The cyst is not a uniform structure. It is a complex and highly organized environment that contains multiple distinct parasite subtypes with specific roles. Each subtype follows a different biological program that contributes to persistence, reactivation, and long term infection. The findings change the scientific understanding of how Toxoplasma survives inside the human body and provide a new view of what is happening inside the brain during chronic infection.
Toxoplasma infects roughly one third of the global population. Most individuals never experience noticeable symptoms, yet the parasite takes permanent residence inside the body. After the acute stage ends, Toxoplasma shifts into a slower growing developmental phase known as the bradyzoite stage. Bradyzoites collect inside tissue cysts, especially in neurons, but they also appear in skeletal and cardiac muscle. These cysts hold hundreds of parasites and resist every available treatment. The persistence of these structures is the primary reason Toxoplasma remains a life long infection. Once formed, a cyst cannot be cleared by the immune system or eliminated by standard therapies.
For decades the internal biology of these cysts has been difficult to study. They are small, buried deep in tissue, and develop slowly. Attempts to recreate them in vitro have produced simplified versions of what occurs inside a living host. Most laboratory approaches rely on alkaline stress to push parasites toward bradyzoite development. These methods generate cyst like forms, but they do not match the full complexity of cysts found in animal brains. As a result, research has focused heavily on the fast growing tachyzoite stage, which grows cleanly in culture and provides enough material for genetic studies. The slower bradyzoite stage inside cysts has been understudied because the parasites cannot be maintained in large numbers and do not behave predictably in vitro.
The new study advances a different approach. Instead of relying on artificial induction of bradyzoites in culture, the researchers harvested cysts directly from chronically infected mice. Mice serve as natural intermediate hosts for Toxoplasma, and their brains can hold thousands of tissue cysts during long term infection. By purifying these cysts and releasing individual bradyzoites through controlled enzymatic digestion, the team was able to analyze single parasites with high resolution. They used single cell RNA sequencing to examine gene expression patterns inside individual bradyzoites. This level of detail revealed an internal landscape that had not been visible before.
The analysis showed that bradyzoites inside a single cyst are not the same. They form at least five major subtypes with distinct transcriptional signatures. These subtypes have different protein profiles, different levels of replication readiness, and different developmental preferences. The discovery overturns the assumption that the cyst contains a single, uniform population of slow growing parasites. Instead, the cyst contains a small ecosystem with subpopulations positioned for different roles in the life cycle.
One of the central findings revolves around a surface antigen called SRS22A. Earlier work showed that Toxoplasma produces a range of SRS proteins that appear on the parasite surface. Many of these proteins have unclear functions, although they are believed to influence interactions with host cells. SRS22A stood out in this study because it appeared at high levels in bradyzoites inside cysts from infected animals. It was almost entirely absent from bradyzoites produced through alkaline stress in laboratory cultures. This difference allowed the researchers to separate bradyzoites into two major categories. SRS22A positive bradyzoites and SRS22A negative bradyzoites followed different developmental paths once released from the cyst.
When SRS22A positive bradyzoites infected new cells, they rapidly initiated conversion into tachyzoites. Tachyzoites are the fast replicating form responsible for acute infection, dissemination, and tissue damage. The presence of SRS22A marked a subtype that was primed to restart the active phase of the life cycle. These parasites produced strong tachyzoite growth in cell culture. In animal experiments, infections seeded with SRS22A positive bradyzoites produced higher parasite loads during the acute stage and higher cyst counts during the chronic stage. This indicated that the SRS22A positive subtype drives reactivation and contributes directly to the spread of infection throughout the host.
SRS22A negative bradyzoites behaved differently. Instead of converting into tachyzoites, they continued to replicate as bradyzoites. They formed new cyst walls in culture and maintained bradyzoite specific markers. This showed that a second developmental route operates alongside reactivation. Some bradyzoites do not switch back to the fast growing form. They continue to expand the cyst population directly. These findings explain why cyst numbers increase over time in infected animals even without clear episodes of reactivation. The internal population includes a subtype designed for silent expansion.
The presence of these two major trajectories indicated that cysts contain prestructured developmental potential. They do not respond uniformly to the environment. Certain bradyzoites are ready for reactivation. Others support maintenance and long term persistence. The new study extended this further by identifying additional subtypes that did not fit neatly into these two categories.
One of these subtypes, labeled Group B in the transcriptomic analysis, contained the highest proportion of SRS22A positive parasites. This group also showed unexpected characteristics. Many Group B bradyzoites lacked expression of BAG1, a heat shock protein that has served as a classic marker for bradyzoite development for more than thirty years. Group B also expressed several proteins normally associated with merozoites, the stage that develops in feline hosts during sexual reproduction. This combination of features suggests that some bradyzoites may be poised to respond to changes in the host environment by triggering either tachyzoite formation or preparation for transmission to a cat. The implications extend beyond typical human infection and point to a deeper flexibility in the life cycle.
Another set of subtypes, labeled Groups C and D, represented the majority of SRS22A negative bradyzoites responsible for cyst maintenance. These groups expressed high levels of SRS9 and other markers linked to cyst wall formation. Their gene expression patterns favored long duration persistence rather than rapid replication. These bradyzoites likely serve as the foundation for stable chronic infection.
A final group, labeled Group E, showed elevated levels of transcripts associated with replication and cell cycle progression. This group may represent the small fraction of bradyzoites capable of limited replication inside the cyst. Earlier research showed that bradyzoites do undergo intermittent replication inside cysts, although the scale is much slower than tachyzoite replication. The discovery of a transcriptomic signature for these parasites provides direct evidence for a growth capable subtype that participates in internal cyst dynamics.
Together these subtypes reveal a level of heterogeneity that contradicts older models. The traditional life cycle diagram showing a linear transition from tachyzoite to bradyzoite to cyst is incomplete. The cyst contains parallel programs running at the same time. Some parasites are prepared for growth. Some are prepared for reactivation. Some are prepared for structural maintenance. Some may be prepared for the next stage of transmission. The system functions as a coordinated but diverse population rather than a uniform state.
The researchers also noted that bradyzoites lose SRS22A expression rapidly when placed into standard cell culture conditions. Within twenty four hours of infecting new cells, the SRS22A signal disappears. This indicates that the signature of in vivo bradyzoites is lost quickly in vitro. It explains why previous in vitro studies did not detect these natural subtypes. The environment inside the brain shapes bradyzoite development in ways that artificial systems cannot reproduce. This gap highlights why the new methods were necessary to uncover the true biology of chronic infection.
The complexity inside the cyst also clarifies why current treatments have had little success. Most drugs target pathways associated with tachyzoite growth. Bradyzoites inside cysts have different metabolic requirements and different gene expression profiles. Even more important, the cyst structure itself contains several subpopulations that respond differently to environmental signals. A drug that suppresses one subtype may have no effect on another. If the SRS22A positive subtype initiates reactivation while the SRS22A negative subtype maintains cyst populations, an effective therapy must address both at the same time. The internal diversity explains why past attempts to eliminate chronic infection have failed and why new strategies must target the specific biology of bradyzoite subtypes.
The study provides strong support for a shift in research priorities. The cyst should be treated as the central structure in chronic toxoplasmosis. Its internal dynamics determine persistence, reactivation, and long term disease risk. A single cyst holds a set of parasite programs that can respond to immune pressure, environmental stress, and host condition. Until those internal programs are understood and controlled, the infection cannot be eliminated.
The findings also highlight the importance of natural host models when studying chronic parasitic infections. Laboratory systems can simplify experimental design, but they do not always reflect the true biology of an organism that adapts to complex environments inside a living host. By analyzing parasites directly from mouse brains, the researchers were able to capture the full spectrum of bradyzoite behavior. Future investigations that focus on in vivo derived cells are likely to reveal additional features that cannot be reproduced in culture.
This new view of cyst biology raises several questions for the field. It is not yet known how these bradyzoite subtypes form within a cyst. They may emerge from early developmental branching decisions or through environmental cues inside the tissue. It is also unclear how the subtypes communicate or whether they influence each other’s behavior. The presence of multiple transcriptional programs inside a single cyst suggests that internal coordination exists, but the specific regulatory signals remain unidentified. The study also hints at epigenetic influence because the subtypes persist reliably across different infections and maintain predictable patterns of gene expression.
Another open question lies in the pathway toward feline transmission. Toxoplasma completes its sexual cycle inside the intestinal cells of cats. For this to occur, bradyzoites swallowed by a cat must activate a developmental route that produces merozoites rather than tachyzoites. The presence of merozoite related genes in Group B bradyzoites suggests that certain subtypes may be primed for this transition before transmission even occurs. This points to a preloaded readiness inside the cyst that prepares the parasite for its next host, although direct demonstration will require further study.
The recognition of multiple bradyzoite subtypes also calls for new diagnostic methods. Current tools cannot distinguish between infections dominated by SRS22A positive or SRS22A negative cyst populations. If different cyst compositions carry different risks for reactivation or disease severity, future diagnostics may need to evaluate the internal structure of cysts rather than rely on general markers of infection. Understanding the internal subtype ratios could predict the potential for reactivation or long term complications.
The work has direct implications for human health because reactivation of chronic infection can cause severe neurological damage, particularly in individuals with weakened immune systems. Toxoplasmic encephalitis remains a significant concern for patients undergoing chemotherapy or immunosuppressive treatment. The new findings show that the bradyzoite subtype responsible for reactivation can be identified by its surface antigen profile. This provides a potential path for targeted intervention.
By defining the architecture inside cysts, the study brings attention to a stage of the life cycle that has been overlooked in both research and clinical discussions. The cyst is not a passive container. It is a controlled structure with different cell types positioned for specific outcomes. This internal diversity is the key to the parasite’s success in long term infection. It ensures survival even in the presence of strong immune pressure and maintains the ability to restart active infection when conditions allow.
The discovery of these subtypes establishes a foundation for the next generation of Toxoplasma research. It opens a clear path toward treatments designed around the internal biology of the cyst rather than the fast growing stage outside it. With the identification of the SRS22A positive reactivation group and the SRS22A negative maintenance group, researchers finally have distinct targets to pursue. Progress in this direction could lead to therapies that limit reactivation risk or reduce the long term burden of chronic infection.
The study demonstrates that the parasite’s long term survival strategy is more sophisticated than expected. The cyst functions as a diversified community where each bradyzoite subtype contributes differently to persistence, reactivation, or structural stability. This complexity explains the resilience of the parasite and provides a framework for understanding why chronic infection has remained untreatable for so long. It also confirms that future treatment strategies must account for the internal heterogeneity of the cyst rather than treating it as a simple dormant form.
Source:
Ulu, A., Srivastava, S., Kachour, N., Le, B. H., White, M. W., & Wilson, E. H. (2026). Bradyzoite subtypes rule the crossroads of Toxoplasma development. Nature Communications.
https://doi.org/10.1038/s41467-026-68489-y
